If You Invested in Cingulate (CINGW)

Cingulate Inc. (CINGW) is a clinical-stage biopharmaceutical company in the pharmaceutical preparation manufacturing industry. The company is focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release™ (PTR™) drug delivery platform. Cingulate’s strategy centers on conditions that are often treated with multiple daily doses and where existing therapies can result in suboptimal symptom control.

Cingulate’s initial therapeutic focus is Attention-Deficit/Hyperactivity Disorder (ADHD), a chronic neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity that impair academic, professional, and social functioning. The company notes that ADHD affects an estimated 20 million individuals in the United States, including approximately 8 million children and 12 million adults. Stimulant medications are widely used in ADHD, but many currently available extended-release formulations still require more than one daily dose and may not provide consistent coverage across the entire active day.

Business Model and PTR™ Platform

Cingulate’s business model is built around its PTR™ platform technology, which is designed to enable once-daily dosing while delivering multiple timed releases of medication. The platform incorporates a proprietary Erosion Barrier Layer (EBL) that controls drug release at specific, pre-defined times. The EBL is enrobed around a drug-containing core, creating a tablet-in-tablet dose form that erodes at a controlled rate until the active drug is released. The EBL formulation, referred to as OralogiK™ or Oralogik™, is licensed from BDD Pharma.

Using this technology, Cingulate is developing product candidates intended to deliver active pharmaceutical ingredients several times a day from a single tablet. The company states that this approach is aimed at conditions where multiple daily dosing is common and where more precise timing of drug release could offer meaningful improvement over existing therapies. Beyond ADHD, Cingulate is also pursuing candidates in anxiety disorders and other neuropsychiatric indications that share similar treatment challenges.

Lead Candidate: CTx-1301 for ADHD

Cingulate’s lead asset is CTx-1301 (dexmethylphenidate or dexmethylphenidate HCl), a once-daily, multi-core, extended-release tablet formulated with the PTR™ platform. According to the company, CTx-1301 is designed to:

• Deliver three precisely timed releases of dexmethylphenidate across the day
• Provide rapid onset of effect
• Maintain entire active-day duration of symptom control
• Offer a smooth pharmacokinetic profile from a single daily dose

Dexmethylphenidate is a stimulant compound approved by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD and is known to increase norepinephrine and dopamine activity in the brain to affect attention and behavior. Cingulate highlights that stimulants remain the gold-standard therapy for ADHD due to their efficacy and safety profile, but that many patients still need an additional “booster” dose later in the day when other extended-release products begin to wear off. CTx-1301 is designed to address these limitations by timing a third release of medication around the point at which other extended-release stimulant products typically lose effect.

CTx-1301 is being evaluated under the FDA’s 505(b)(2) regulatory pathway, which allows a sponsor to reference existing data on an already approved active ingredient while demonstrating differentiated clinical benefit through a novel delivery mechanism. Cingulate reports that adult and pediatric Phase 3 trials have been completed and that CTx-1301 has shown improvements in ADHD signs and symptoms in both adult and pediatric patients. In clinical studies, the company states that CTx-1301 demonstrated rapid onset of effect, sustained efficacy into the afternoon and evening hours, and a safety and tolerability profile consistent with other long-acting methylphenidate products, with no serious treatment-emergent adverse events reported.

Regulatory Progress and Late-Stage Development

Cingulate has submitted a New Drug Application (NDA) to the FDA for CTx-1301 for the treatment of ADHD in children and adults. The company reports that the NDA was accepted for review and that the FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026. NDA acceptance signifies that the submission is sufficiently complete to permit substantive review, but the company notes that acceptance does not imply approval or guarantee any particular outcome.

The NDA submission followed a positive pre-NDA meeting with the FDA and completion of adult and pediatric Phase 3 trials, as well as all FDA-requested studies and Chemistry, Manufacturing, and Controls (CMC) work. Cingulate also received a fiscal year 2025 PDUFA fee waiver under the small business waiver provision of the Federal Food, Drug, and Cosmetic Act, which the company states will save approximately $4.3 million in filing fees for the CTx-1301 NDA.

Manufacturing and Commercial Readiness

To support potential commercialization, Cingulate has entered into a commercial supply agreement with Bend Bio Sciences for the manufacturing of CTx-1301. Under this agreement, Bend Bio Sciences will serve as the exclusive commercial manufacturer of CTx-1301 in the United States through 2028, if the product is approved by the FDA. Cingulate has committed to purchasing 100% of its overall U.S. commercial supply of CTx-1301 from Bend following and subject to any FDA approval. The company indicates that process transfer and scale-up production using commercial-grade equipment have been completed, providing early validation and supporting supply chain readiness.

On the commercial strategy side, Cingulate has partnered with Indegene, a digital-first life sciences commercialization company. According to Cingulate, this partnership is built around an AI-driven, data-rich platform that aims to optimize prescriber reach, payer access, and patient support as the company prepares for a potential launch of CTx-1301. The company also notes that it is advancing launch readiness activities and has highlighted variable-cost commercial structures intended to align spending with growth milestones.

Pipeline Beyond CTx-1301

While CTx-1301 is the lead candidate, Cingulate describes a broader pipeline of PTR™-enabled product candidates. The company indicates that it is developing ADHD and anxiety disorder product candidates capable of achieving true once-daily dosing using the PTR platform. In addition to ADHD and anxiety, Cingulate states that it intends to identify and develop additional product candidates in other therapeutic areas where one or more active pharmaceutical ingredients must be delivered several times a day at specific, predefined time intervals and where improved treatment consistency over existing therapies may be beneficial.

In its registration statement, Cingulate also references other proprietary stimulant candidates, such as CTx-1302 (dextroamphetamine), which are being developed for the treatment of ADHD across children, adolescents, and adults. These candidates are designed to address the same core limitations in current stimulant therapies that CTx-1301 targets, such as delayed onset, inconsistent duration, and the need for multiple daily doses.

Capital Markets and Corporate Structure

Cingulate Inc. is headquartered in Kansas City, Kansas. Its common stock trades on the Nasdaq Capital Market under the symbol CING, and its publicly listed warrants trade under the symbol CINGW. The warrants are exercisable for shares of common stock and are also listed on Nasdaq, as reflected in multiple SEC filings that identify CINGW as warrants exercisable for common stock on the Nasdaq Capital Market.

The company has pursued various financing arrangements to fund development and pre-commercial activities. For example, Cingulate entered into a purchase agreement with Lincoln Park Capital Fund, LLC, providing for up to $25 million of committed equity financing, and registered shares related to that agreement on Form S-1/A. The company has also issued equity and options in unregistered transactions, as disclosed in several Form 8-K filings, including shares issued to lenders in exchange for portions of outstanding debt and option awards granted to officers as inducement grants.

Governance and Recent Corporate Developments

Cingulate’s SEC filings describe several corporate governance and management changes. In August 2025, the board of directors appointed an Executive Chairman and placed the then Chief Executive Officer on administrative leave following a legal charge, while naming the Chief Financial Officer as interim Chief Executive Officer. The board also made changes to audit committee leadership and disclosed separation arrangements with a former executive officer. These developments are documented in Form 8-K filings and a late filing notification (Form 12b-25), which cites management changes as a reason additional time was needed to complete a quarterly report.

The company’s proxy materials further describe a special meeting of stockholders to consider approval of the issuance of more than 20% of the company’s outstanding common stock under the Lincoln Park Capital purchase agreement, in order to comply with Nasdaq Listing Rule 5635(d). The proxy statement outlines the Issuance Proposal and an Adjournment Proposal, reflecting Cingulate’s use of equity financing as part of its capital strategy.

Industry Context and Focus

Cingulate positions itself within the ADHD treatment landscape as a developer of once-daily stimulant formulations that seek to provide active-day coverage from a single dose. The company repeatedly emphasizes the unmet need for therapies that avoid the need for midday booster doses and that maintain consistent symptom control throughout the day. Its PTR™ platform and lead candidate CTx-1301 are intended to address these challenges by engineering precise timing of drug release within a single tablet.

In addition to ADHD, Cingulate highlights anxiety and other neuropsychiatric indications as areas where its timed-release technology may be applicable. The company’s stated goal is to improve patient outcomes in conditions characterized by burdensome daily dosing regimens and treatment gaps, using a manufacturing and development approach grounded in its proprietary drug delivery platform.